CIK 0001404644
- Non-accelerated filer
- Smaller reporting company
Neurogene Inc.
Sign in to watch- Ticker
- NGNE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 980542593
- Phone
- +1 877-237-5020
- Business address
- 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY, 10011
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-12-17 | JOHNSON & JOHNSON 10% owner | Sale | −1,593 | $7.58 | $12K | 1,342,094 |
| 2014-12-16 | JOHNSON & JOHNSON 10% owner | Sale | −6,507 | $7.63 | $50K | 1,343,687 |
| 2014-12-12 | JOHNSON & JOHNSON 10% owner | Sale | −3,645 | $7.51 | $27K | 1,350,194 |
| 2014-12-11 | JOHNSON & JOHNSON 10% owner | Sale | −1,355 | $7.50 | $10K | 1,353,839 |
| 2014-12-10 | JOHNSON & JOHNSON 10% owner | Sale | −1,300 | $7.70 | $10K | 1,355,194 |
| 2014-12-09 | JOHNSON & JOHNSON 10% owner | Sale | −5,000 | $7.73 | $39K | 1,356,494 |
| 2014-12-08 | JOHNSON & JOHNSON 10% owner | Sale | −2,000 | $7.69 | $15K | 1,361,494 |
| 2014-12-05 | JOHNSON & JOHNSON 10% owner | Sale | −4,200 | $7.78 | $33K | 1,363,494 |
| 2014-12-04 | JOHNSON & JOHNSON 10% owner | Sale | −10,073 | $7.76 | $78K | 1,367,694 |
| 2014-12-03 | JOHNSON & JOHNSON 10% owner | Sale | −1,627 | $7.75 | $13K | 1,377,767 |
| 2014-12-01 | JOHNSON & JOHNSON 10% owner | Sale | −1,200 | $7.54 | $9K | 1,379,394 |
| 2014-11-26 | JOHNSON & JOHNSON 10% owner | Sale | −500 | $7.60 | $4K | 1,380,594 |
| 2014-11-25 | JOHNSON & JOHNSON 10% owner | Sale | −1,500 | $7.80 | $12K | 1,381,094 |
| 2014-11-24 | JOHNSON & JOHNSON 10% owner | Sale | −4,000 | $8.02 | $32K | 1,382,594 |
| 2014-11-21 | JOHNSON & JOHNSON 10% owner | Sale | −2,400 | $8.25 | $20K | 1,386,594 |
| 2014-11-20 | JOHNSON & JOHNSON 10% owner | Sale | −3,100 | $8.21 | $25K | 1,388,994 |
| 2014-05-08 | SHREWSBURY STEPHEN B CMO; Senior VP Clinical Dev. | Grant or award · Stock Option (Right to Buy) | +31,250 | 31,250 | ||
| 2014-05-08 | Main David President and CEO | Grant or award · Stock Option (Right to Buy) | +65,000 | 65,000 | ||
| 2014-05-08 | MacKenzie Lloyd VP Technical Operations | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2014-05-08 | Alam Kamran CFO, Vice President Finance | Grant or award · Stock Option (Right to Buy) | +31,250 | 31,250 |
Page 23 of 27 · 537 trades